ontegimod
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2025 (NCT06904378)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Integrin alpha MACTIVATOR
ITGAM activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07107659 | Early Phase 1 (Phase 1) | Sep 4, 2026 | Rockefeller University, University of Texas, Galveston |
| NCT06904378 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2025 | National Cancer Institute (NCI), Washington University in St. Louis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| Rockefeller University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| University of Texas, Galveston | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1